Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer

Journal of Cell Communication and Signaling

Volumn 9, Issue 1, 2015, Pages 101-102

  Roberts, David D ^a   Kaur, Sukhbir ^a   Soto Pantoja, David R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cathepsin S; CD47; Chemoresistance; NF B; Tumor initiating cells

Indexed keywords

EID: 84939935750     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-015-0283-9     Document Type: Article

References (14)

1. Barclay AN, van den Berg TK (2014) The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32:25–50
2. Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, Andre P, Mely Y, Mousli M, Gies JP (2015) CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells. Anticancer Res 35:149–157
3. Campbell IG, Freemont PS, Foulkes W, Trowsdale J (1992) An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res 52:5416–5420
4. Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24:225–232
5. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD (2009) Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 9:182–194
6. Kaur S, Soto-Pantoja DR, Stein EV, Liu C, Elkahloun AG, Pendrak ML, Nicolae A, Singh SP, Nie Z, Levens D, Isenberg JS, Roberts DD (2013) Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep 3:1673
7. Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, Ng IO (2014) Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60:179–191
8. O’Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L, Duan W (2014) Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett 344:180–187
9. Soto-Pantoja DR, Miller TW, Frazier WA, Roberts DD (2012) Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci U S A 109:E2842
10. Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, Degraff WG, Wink DA, Berzofsky JA, Roberts DD (2014) CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74:6771–6783
11. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, Dick JE, Danska JS (2007) Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8:1313–1323
12. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109:6662–6667
13. Zhao XW, van Beek EM, Schornagel K, Van Der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, Birnbaum D, van Elsas A, Kuijpers TW, Bertucci F, van den Berg TK (2011) CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 108:18342–18347
14. Zhao XW, Matlung HL, Kuijpers TW, van den Berg TK (2012) On the mechanism of CD47 targeting in cancer. Proc Natl Acad Sci U S A 109:E2843